Will Auvelity & Other Drugs Aid AXSM's Growth Amid Stiff Competition?

Axsome Therapeutics’ (AXSM) Auvelity (AXS-05) was launched in the United States in 2022 for the treatment of major depressive disorder (MDD), making it the first approved drug in the company’s portfolio.Auvelity generated sales worth $291.4 million in 2024, reflecting an increase of 124% year over year in the United States. Sales of the drug are being driven by an increase in unit sales volume and the momentum is likely to continue in 2025.Axsome is also working to expand the label of Auvelity for the large ...